Anaplastic lymphoma kinase (ALK) rearrangement is detected in 3–7% of patients with non-
small-cell lung cancer. Crizotinib is an ALK inhibitor, which was approved in 2011 for the …

Introduction: Crizotinib is a first-in-class ALK tyrosine kinase inhibitor (TKI), which has
proven its superiority over standard platinum-based chemotherapy for the first-line therapy of …

Anaplastic lymphoma kinase (ALK) rearrangement is one of the oncogenes in non-small cell
lung cancer (NSCLC) identified in 2007. The PROFILE trials demonstrated that patients with …

Importance The identification of anaplastic lymphoma kinase (ALK) rearrangements in 2-5%
of non-small cell lung cancer (NSCLC) patients led to the rapid clinical development of its …

Crizotinib is an oral inhibitor of anaplastic lymphoma kinase (ALK) with remarkable clinical
activity in patients suffering from ALK-rearranged non-small cell lung cancer (NSCLC) …

Non–small cell lung cancers (NSCLCs) harboring anaplastic lymphoma kinase (ALK)
rearrangement are generally responsive to treatment with ALK tyrosine kinase inhibitors …

The identification of oncogenic driver mutations in non-small cell lung cancer (NSCLC) has
led to a paradigm shift and the development of specific molecular treatments. Tumors …

Patients are diagnosed as anaplastic lymphoma kinase (ALK) positive, ie exhibiting the ALK
rearrangement, and comprise 3–7% of non-small-cell lung cancer (NSCLC) cases. Three …

Introduction Anaplastic lymphoma kinase (ALK) inhibitors are widely known to contribute to
the long-term survival of ALK-rearranged non-small cell lung cancer (NSCLC) patients …

Crizotinib was the first clinically available anaplastic lymphoma kinase (ALK) inhibitor,
showing remarkable activity against ALK-rearranged non-small-cell lung cancer (NSCLC) …